OXM-104 / Nordic Biosci - LARVOL DELTA

OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes. (PubMed, Eur J Pharmacol) - "These results show that dual GLP-1 and glucagon receptor agonism is superior to GLP-1 alone. OXM-104 was found to be a promising therapeutic candidate for the treatment of metabolic complications such as obesity, type 2 diabetes and NASH."

Journal • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Obesity • Type 2 Diabetes Mellitus